Tvardi Therapeutics is trading at $0.92, up 6.97%, with no clear company-specific announcement explaining its November 6 pre-market rise.
- Its investor-relations page lists an October 14 conference announcement and a September 24 preclinical-data update as its latest releases.
- Broader-market signals in the supplied context are mixed, and available evidence does not establish a specific cause for the gain.